Trial Profile
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs Sarecycline (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Registrational
- Sponsors Actavis; Almirall S.A.
- 06 Dec 2019 According to an Almirall S.A. Media Release, company announced publication of data from this trial.
- 06 Dec 2019 According to an Almirall S.A. Media Release, David M. Pariser, MD, FACP, FAAD of the Virginia Clinical Research Center in Norfolk, Virginia and principal investigator for the study.
- 06 Dec 2019 Results presented in an Almirall S.A. Media Release.